Agilent Technologies (NYSE:A) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Agilent Technologies (NYSE:A) issued its quarterly earnings data on Wednesday. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.49 by $0.13, FiscalAI reports. The firm had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.37 earnings per share. Agilent Technologies updated its Q4 2026 guidance to 1.710-1.740 EPS and its FY 2026 guidance to 6.180-6.210 EPS.

Here are the key takeaways from Agilent Technologies’ conference call:

• Agilent delivered a strong Q3 beat and raised its outlook. Revenue grew 7.3% organically to $1.88 billion, while adjusted EPS excluding tariff refunds rose 14% to $1.56; full-year core growth guidance increased to 5.8%-6.0% and adjusted EPS guidance to $6.12-$6.15.
• Pharma, China, and key applied markets showed broad-based momentum. Pharma grew 12%, China grew 9% versus expectations for flat growth, and chemicals and advanced materials grew 7%, supported by biotech funding, GLP-1 demand, PFAS testing, semiconductor investment, and AI infrastructure spending.
• New products and replacement cycles are supporting demand. LC revenue grew low double digits, book-to-bill remained above one for the 10th consecutive quarter, and early orders for the 9500 ICP-MS, flagship GC systems, and Altura columns exceeded expectations.
• Ignite drove significant operating leverage. Q3 operating margin excluding tariff refunds expanded 210 basis points year over year to 27.2%, with strategic pricing contributing approximately 200 basis points and operational improvements helping offset inflationary and supply-chain pressures.
• The specialty CDMO outlook is strong longer term but faces near-term timing pressure. The business grew nearly 30% in Q3, with about 75% of fiscal 2027 Train C capacity already backed by purchase orders, but Q4 growth is expected to be flat because of regulatory-submission timing and a difficult comparison exceeding 40% growth.

Agilent Technologies Stock Up 0.3%

Shares of NYSE:A opened at $155.16 on Thursday. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $139.16 and a two-hundred day simple moving average of $126.65. Agilent Technologies has a 12-month low of $108.35 and a 12-month high of $160.51. The stock has a market capitalization of $43.82 billion, a price-to-earnings ratio of 31.16, a PEG ratio of 2.73 and a beta of 1.25.

Hedge Funds Weigh In On Agilent Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming purchased a new stake in shares of Agilent Technologies during the second quarter valued at approximately $35,000. Transamerica Financial Advisors LLC lifted its position in Agilent Technologies by 180.8% in the 4th quarter. Transamerica Financial Advisors LLC now owns 337 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 217 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in Agilent Technologies during the 3rd quarter valued at $49,000. DV Equities LLC bought a new stake in shares of Agilent Technologies in the 4th quarter worth $54,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Agilent Technologies in the 4th quarter worth $58,000.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their price target on shares of Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Piper Sandler initiated coverage on shares of Agilent Technologies in a research report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 target price on the stock. HSBC decreased their price target on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Finally, Wolfe Research reissued a “hold” rating on shares of Agilent Technologies in a research note on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $160.24.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and ahead of the approximately $1.84 billion analyst estimate. Adjusted earnings were $1.62 per share, above the $1.48-$1.49 consensus and up from $1.37 a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Management raised fiscal 2026 adjusted EPS guidance to $6.18-$6.21, above the $6.06 consensus, and set revenue guidance at approximately $7.5 billion, slightly ahead of expectations. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus. Agilent Boosts FY View on Higher 3Q Profit, Revenue
• Positive Sentiment: Profitability and cash generation strengthened. Operating profit rose 23.3% to $444 million, while operating cash flow increased 43.4% to $519 million. The company ended the quarter with approximately $1.8 billion in cash and relatively moderate leverage. Agilent Technologies Stock Rises on Q3 2026 Earnings
• Neutral Sentiment: The earnings beat and guidance increase helped push the stock toward a recent high. However, Agilent already trades near its 52-week high, with a P/E ratio above 31 and a median analyst price target of about $155, suggesting much of the improved outlook may already be reflected in the valuation.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.